NCT02730130View on ClinicalTrials.gov

Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 3, 2016

Primary Completion Date

September 26, 2017

Study Completion Date

October 12, 2022

Conditions

Breast CancerMetastatic Triple Negative

Interventions

DRUG

Pembrolizumab

RADIATION

Radiotherapy

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Cedars-Sinai Medical Center, Los Angeles

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Cedars-Sinai Medical Center

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02730130 - Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | Biotech Hunter | Biotech Hunter